BioNTech SE is a Biotechnology & Immunotherapy company headquartered in Mainz, Germany. In FY2025, it reported $3.2B in site-standard revenue, based on official EUR2.8699B native-currency revenue and a roughly $1.26B net loss. It had about 7,807 employees and is led by Prof. Ugur Sahin, M.D..
How BioNTech Makes Money
BioNTech makes money from COVID-19 vaccine collaboration revenue, partner payments, development collaborations, service revenue, and future oncology product commercialization. Its customers include governments, public-health systems, pharma partners, oncology patients, clinical investigators, hospitals, and future commercial oncology prescribers. The current revenue driver is still Comirnaty-related and collaboration revenue, while long-term value depends on oncology assets reaching approval.
BioNTech Strategy
BioNTech competes by using mRNA science, immuno-oncology platforms, partnerships, and a large cash balance to build a multi-product oncology company after the COVID vaccine boom. The strategic focus is turning a broad oncology pipeline into approved products while keeping enough COVID and collaboration revenue to fund R&D.
BioNTech Financials
BioNTech reported FY2025 revenue of EUR2.8699B, a net loss of EUR1.1361B, R&D expenses of EUR2.1049B, cash and security investments of EUR17.2356B, and 7,807 full-time equivalent employees. BioNTech reported a FY2025 net loss of EUR1.1361B, shown here as roughly a $1.26B net loss.
BioNTech Competitive Position
BioNTech's advantage is the combination of validated mRNA expertise, deep immunology, a large cash and securities position, and partnerships that give it global development reach. It competes with Moderna, Pfizer, Gilead Sciences and other companies across Biotechnology & Immunotherapy.
BioNTech Risks
BioNTech's biggest risk is that COVID-19 vaccine revenue keeps declining before oncology products become commercial, leaving high R&D spend dependent on clinical-trial success.
